ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM
Abstract Number: 1249
Association between Positive Emotions and Physical Function in Early Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 1264
Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
10:30AM-12:30PM
Abstract Number: 1252
Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
10:30AM-12:30PM
Abstract Number: 1268
Development of the LupusCoach Chatbot: Results of a Focus Group
10:30AM-12:30PM
Abstract Number: 1269
Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions
10:30AM-12:30PM
Abstract Number: 1263
Health Literacy diversity among rheumatology patients: insights from a tertiary rheumatology centre
10:30AM-12:30PM
Abstract Number: 1270
Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study
10:30AM-12:30PM
Abstract Number: 1260
Increasing Zoster Vaccination Rates in Immunosuppressed Veterans at the North Texas VA Medical Center Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 1257
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
10:30AM-12:30PM
Abstract Number: 1255
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
10:30AM-12:30PM
Abstract Number: 1271
Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
10:30AM-12:30PM
Abstract Number: 1259
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
10:30AM-12:30PM
Abstract Number: 1248
Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 1250
Patient Perceptions of the National Tele-Rheumatology Program: A Mixed Methods Study
10:30AM-12:30PM
Abstract Number: 1265
Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations
10:30AM-12:30PM
Abstract Number: 1253
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
10:30AM-12:30PM
Abstract Number: 1267
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
10:30AM-12:30PM
Abstract Number: 1262
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
10:30AM-12:30PM
Abstract Number: 1256
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1266
Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
10:30AM-12:30PM
Abstract Number: 1251
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
10:30AM-12:30PM
Abstract Number: 1254
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
10:30AM-12:30PM
Abstract Number: 1261
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology